The evolved World Health Organization/International Programme on Chemical Safety mode of action (MOA) framework provides a structure for evaluating evidence in pathways of causally linked key events (KE) leading to adverse health effects. Although employed globally, variability in use of the MOA framework has led to different interpretations of the sufficiency of evidence in support of hypothesized MOAs. A proof of concept extension of the MOA framework is proposed for scoring confidence in the supporting data to improve scientific justification for MOA use in characterizing hazards and selecting dose-response extrapolation methods for specific chemicals. This involves selecting hypothesized MOAs, and then, for each MOA, scoring the weight of evidence (WOE) in support of causality for each KE using evolved Bradford Hill causal considerations (biological plausibility, essentiality, dose-response concordance, consistency, and analogy). This early proof of concept method is demonstrated by comparing two potential MOAs (mutagenicity and peroxisome proliferator activated receptor-alpha) for clofibrate, a rodent liver carcinogen. Quantitative confidence scoring of hypothesized MOAs is shown to be useful in characterizing the likely operative MOA. To guide method refinement and future confidence scoring for a spectrum of MOAs, areas warranting further focus and lessons learned, including the need to incorporate a narrative discussion of the weights used in the evaluation and an overall evaluation of the plausibility of the outcome, are presented.
Introduction
Since its introduction in 2001, the mode of action (MOA) and human relevance framework (hereafter referred to as the MOA framework) has proved to be a useful tool for organizing and evaluating data to inform human health risk assessments of chemical exposures (Sonich-Mullin et al., 2001; USEPA, 2001; USEPA, 2005a,b; Boobis et al., 2006; Boobis et al., 2008; Carmichael et al., 2011; Meek et al., 2014a; Elcombe et al., 2014; Budinsky et al., 2014; Corton et al., 2014) . The MOA framework is an analytical approach to evaluate the weight of evidence (WOE) in support of a postulated MOA. Table 1 presents a number of the fundamental terms and definitions of the critical elements of the MOA framework. The MOA framework has been widely adopted in regulatory guidance and hazard characterizations/risk assessments around the world, including those of the European Food Safety Authority (EFSA), the Joint Food and Agriculture Organization (FAO)/WHO Meeting on Pesticide Residues (JMPR), the European Chemicals Agency (ECHA), and the United States Environmental Protection Agency (USEPA). This framework has evolved and advanced largely due to improved understanding of biological pathways/disease processes and experience in applying causality criteria to evaluate different lines of scientific evidence. The MOA framework has been extended to enable the holistic integration of evidence at multiple levels of biological organization, and the evaluation for species concordance of effects in the context of environmental levels of exposure (Meek et al., 2014a,b) .
While the MOA framework continues to evolve as a basis to increase transparency and defensibility of decisions, explicit and systematic analysis of the WOE supporting postulated MOAs is at times lacking. There is also noticeable variation in the application of the MOA framework within and across users, often leading to different interpretations of the sufficiency of scientific evidence to support a given MOA and conclusions regarding relative support for alternative MOAs (Dourson et al., 2013) . The scientific justification for assessing human relevance and selecting dose-response extrapolation methods for quantifying risks at environmentally relevant levels of exposure is highly dependent upon the determination of the likely operative MOA. For example, USEPA's Cancer Guidelines (USEPA, 2005b) invoke a linear extrapolation approach when there is indication of a mutagenic MOA and as a default option "in the absence of sufficiently, scientifically justifiable mode of action information." Thus, to enhance documentation and demonstration of "sufficiently, scientifically justifiable mode of action information" there is a pressing need to improve the approaches for conducting comparative quantitative WOE evaluations to aid in identifying the likely operative MOA, particularly for carcinogens where quantitation of cancer risks is a key factor underpinning many risk management actions. Hence, as an initial proof of concept, we have extended the MOA framework by proposing an approach for evaluating the supporting data for potential MOAs that enables quantitative scoring of the confidence in each. The method is illustrated by analyzing the dataset of clofibrate, a rodent liver carcinogen, and comparing confidence scores for two postulated MOAs: mutagenic and peroxisome proliferator activated receptor-alpha (PPARa) agonism.
Quantitative comparative confidence scoring methodology
A MOA framework analysis presupposes that the WOE for an adverse effect in experimental animals has been evaluated and deemed sufficient as a basis for delineation of the critical effect (Boobis et al., 2006) . After such a determination, potential MOAs are postulated to describe how the chemical exposure and adverse effect may be biologically linked, and the relative WOE and scientific confidence in the supporting mechanistic data for these hypothesized MOAs is compared (Meek et al., 2014a,b; Borgert et al., 2015) . This qualitative analysis in support of a MOA involves two stages: (1) scoping of potential MOAs; and (2) consideration of qualitative comparative WOE of the supporting data. Our method, which is the focus of this paper, adds quantitative WOE confidence scoring as a third stage. This third stage has been organized into eight discrete steps which are presented in Table 2 and discussed in greater detail in the following sections. This quantitative approach builds on the qualitative assessment step by scoring the evolved Bradford Hill causal considerations relied upon in the qualitative evidence integration and evaluation (Meek et al., 2014a,b; OECD, 2016; Becker et al., 2015) . This quantitative scoring facilitates identification of the more likely operative (i.e., best supported) MOA therein informing the appropriate methodology for doseresponse analysis to estimate potential human risks at environmental levels of exposure and/or assessing human relevance. In addition, the approach provides for a transparent and explicit delineation of science judgment versus science policy approaches based on the selection of higher or lower confidence options. An established MOA or AOP, while desirable, is not necessarily a requirement; the methodology proposed here can also be applied early in the AOP/MOA development process as a basis to identify and prioritize critical data gaps. However, in all cases, before embarking on this quantitative confidence scoring method, the supporting evidence should be systematically gathered, relevance, reliability and quality determined, and then the postulated MOAs should undergo qualitative WOE evaluation.
Identify postulated MOA(s) (step 1)
The overall objective is to assess the comparative confidence in hypothesized MOAs for a critical effect of a specific chemical in order to identify the likely operative (best supported) MOA. The method begins with identifying potential scientifically plausible MOAs. This entails consideration of documented biological pathways, the chemical-specific database, as well as relevant information on related chemicals and is addressed in more detail in Boobis et al., 2006; Boobis et al., 2008; Carmichael et al., 2011; Meek et al., 2014a,b . For cancer outcomes, for example, it is common to consider a mutagenic MOA hypothesis if there are data demonstrating that the chemical causes some form of genotoxicity (USEPA, 2005) . It may also be useful to consider hypotheses for well characterized pathways including those for species-specific responses that are generally considered to be qualitatively irrelevant or quantitatively less relevant to humans such as rodent liver tumors via CAR/PXR (Elcombe et al., 2014) , and PPARa (Corton et al., 2014; Klaunig et al., 2003) ; male rat kidney tumors secondary to alpha(2)u-globulin-induced nephropathy (USEPA, 1991; Cohen and Arnold, 2011) ; male rat kidney tumors secondary to chronic progressive nephropathy (Hard et al., 2013) ; rat thyroid follicular cell tumors associated with decreased T 3 /T 4 and increased TSH (USEPA, 1998; Cohen and Arnold, 2011) ; female rat mammary gland tumors due to accelerating the reproductive aging process, and prolonged exposure to endogenous estrogen and prolactin (Simpkins et al., 2011) ; female rat endometrial adenocarcinomas due to accelerating the reproductive aging process and estrogen dominance (Klaunig et al., 2016) ; rat Leydig cell tumors induced by GnRH and dopamine agonists (Rasoulpour et al., 2014) ; and tumors in specific organs in rodents that differ from humans structurally and/or physiologically (e.g., rodent forestomach tumors; Proctor et al., 2007) . In addition to standard literature searches, the more recently developed AOP Wiki (https://aopwiki.org/wiki/index.php/ Main_Page) is a valuable resource for the identification of potentially relevant biological pathways that may inform the selection of hypothesized MOAs for a specific chemical and a specific adverse outcome. This requires the consideration of the extent to which chemical-specific data indicate that a critical effect is likely associated with the pathway in a documented AOP (Fig. 1) , and integration of the associated determinations of confidence in the extent of biological plausibility and empirical support of KERs and essentiality of KEs for the AOP. (Meek et al., 2014a,b) . 2. Qualitatively evaluate the evidence in support of, or inconsistent with, the KEs/KERs (Section 2.2) using the evolved Bradford Hill causal considerations. 3. Quantitatively rate each KE/KER using the evolved Bradford Hill causal considerations (Section 2.3.1). 4. Derive the composite score for each KE/KER by multiplying the quantitative rating score by the weight assigned for each of the evolved Bradford Hill causal considerations and adjust based on the MOA evidentiary value of each KE/KER ( P (weight Â rate Â evidentiary value) ¼ KE/KER score) (Section 2.3.2). 5. Integrate the evidence of causality for the MOA by calculating the sum of the scores for all KEs/KERs and then dividing by the total maximum score to derive the "MOA confidence score" (Section 2.4). 6. Compare the quantitative confidence scores for the hypothesized MOAs, and select the MOA(s) for which confidence in the supporting data is highest (Section 2.4). 7. Depending on the relative confidence in the supporting data for one or more hypothesized MOA(s), consider species concordance or human relevance in the next step (see Supplemental Material). 8. Characterize the analysis to include a narrative discussion of the comparative confidence scores, uncertainties, KEs/KERs where additional studies would bolster confidence because the existing causal evidence is weak, and implications with respect to potential hazards and selection of the dose-response extrapolation method(s) for evaluating human health risks a Steps 3e6 differentiate the quantitative from qualitative assessment. In addition, compared to the qualitative approach, quantitative scoring provides additional transparency to the scientific justification for the characterizations and determinations made in step 8. Fig. 1 . Illustrating the use of an established MOA as a means to align data from a specific chemical to support a MOA analysis for that chemical.
Qualitatively evaluate the evidence in support/inconsistent with the KE/KER (step 2)
Once the MOA hypotheses have been explicitly formulated, the available data should be selected, analyzed, and the relevance and reliability determined. Initially, the chemical-specific data are summarized and categorized qualitatively using evolved Bradford Hill causal considerations according to whether the data are "supportive" or "potentially inconsistent" for the KEs/KERs (Meek et al., 2014a,b) . Based on this qualitative assessment, MOA hypotheses that are inconsistent with data should be explained and documented in the MOA framework analysis; the necessity and utility of quantitative scoring should be carefully considered before proceeding. The quantitative confidence scoring method next proceeds by systematically evaluating the evidence using the evolved Bradford Hill causal considerations: biological plausibility, essentiality, empirical evidence of dose-response, incidence and temporal concordance, consistency (among different biological contexts), and analogy (consistency across structurally similar chemicals).
The definitions, associated questions and degree of evidence provided for each evolved Bradford Hill causal consideration (Table 3) have been drawn from, and informed by, OECD, 2016; Meek et al., 2014a,b; Becker et al., 2015 . The individual or series of KEs are evaluated against the defining question for each evolved Bradford Hill causal consideration, using the WOE rating categories (Table 4) to guide the determinations for scoring. These evaluations and scientific judgments of WOE are not binary decisions; the qualitative rating includes summary descriptors such as strong, moderate or weak. While the qualitative rating scale is not meant to be rigid, or prescriptive, the rating category should describe the general strength of the integrated body of evidence, giving due consideration to both negative and positive high quality studies. Consequently, the qualitative considerations of WOE in the evolved MOA framework have been extended by delineation of explicit rating categories for counter evidence (i.e., weak-, moderate-, or strong-counter evidence) to facilitate quantitation in the next step. The relative scoring, while drawing on collective experience, is necessarily preliminary at this point and envisaged to be refined and improved based on experience with additional case studies.
Quantitatively rate each KE/KER using the Bradford Hill causal considerations (step 3)
In this initial proposed version of the quantitative confidence scoring method for comparing hypothesized MOAs for the induction of an adverse outcome by a specific chemical, a simple arithmetic method was developed to characterize overall confidence scores. Each qualitative evidence rating category is translated into a quantitative evidence rating based on the conversions described in Table 4 .
While scoring from 0 to 3, ranging from no evidence to strong evidence is intuitive and reflects most current MOA WOE evaluation practices, the quantitative confidence scoring method we are proposing also includes scoring counter evidence as weak, moderate or strong counter evidence on a scale of À1 to À3. This explicitly calls for the counter evidence (and inconsistent evidence) to be considered first qualitatively (Meek et al., 2014a,b) and then quantitatively. The rationale for treating counter evidence in this manner is that it is necessary to equally consider and weigh both positive and negative or contradictory studies (Fenner-Crisp and Dellarco, 2016) . This approach in dealing with counter evidence is similar to that described by Adami et al., 2011 and distinguishes evidence of the absence of a response for a KE (i.e., WOE that a response is not elicited) from an absence of evidence (i.e., complete lack of, or limited, evidence of a response).
The need for scoring counter evidence can be illustrated using mutagenicity as an example. It is not uncommon to encounter datasets with "weak" empirical evidence for a mutagenic MOA. For example, for carbon tetrachloride (USEPA, 2008) , as is common for a number of chemical-specific datasets, the results of the majority of genotoxicity assays are negative, but there are a few positive findings. In large datasets such as this, it is entirely possible that such a response occurred by chance alone, or that the response is related to high doses/concentrations and, therefore, of questionable relevance to the likely operative MOA for tumorigenesis. Without considering the extent of counter evidence, a qualitative rating in such a case could potentially be described as weak or limited. This would ignore the substantial amount of the mechanistic data that has the most evidentiary valuedthe vast majority of studies that are inconsistent with the chemical acting via a mutagenic mode of action, in particular the overwhelmingly negative results for mutagenicity (Manibusan et al., 2007; Meek et al., 2014b) . The explicit inclusion of scoring counter evidence helps avoid such indecisive assessments.
Assigning weights to each of the evolved Bradford Hill causal considerations
Each evolved Bradford Hill causal consideration has been given a numerical weight in accordance with their ranked importance, with a summed maximum of 100% (Table 5 ). These numerical weights are consistent with the hierarchy described in Meek et al. (2014b) which rank ordered the evolved Bradford Hill causal considerations as: 1) biological plausibility; 2) essentiality; 3) empirical support, including dose-response, incidence, and temporal concordance(s); 4) consistency; and 5) analogy. In extending the MOA framework for quantitative confidence scoring, for the empirical support element, two sub-criteria are considered 1) dose-response and incidence concordance and 2) temporal concordance; each is afforded 50% of the total weight assigned for empirical support (Tables 3 and 5 ). These numerical hierarchical weights, as well as the evidence rating categories and scoring values, have been proposed based on collective experience as an initial basis to explore the utility of the method, fully recognizing the need to solicit additional input from the broader scientific community (see Table 13 ).
Biological plausibility is included in this prototype MOA confidence scoring approach as a critical element of the causal analysis, but it has not been weighted or scored. Biological plausibility characterizes the degree to which the scientific community has accepted an established mechanistic basis for the steps (KEs and KERs) in the pathway that culminate in the adverse effect being considered OECD, 2016) . In essence, it derives from the degree of understanding of a biological pathway based on accumulated scientific knowledge from investigative research and therapeutic medicine on disease processes, and is often based on consideration of effects of a variety of chemicals and other stressors at the molecular, cellular and organ level. Exploring approaches for scoring biological plausibility has been identified as a priority area for additional development of the confidence scoring method and as a key area of focus for additional case examples as these are developed (see Table 13 ).
Experimental inquiry of essentiality focuses specifically on the interplay of causal linkages of KEs in the context of the MOA (i.e., the extent to which modulation or prevention of a KE impacts other KEs in the pathway). Consistent with the procedures and practices for developing AOPs, the essentiality of the KEs within the AOP/ MOA is considered collectively since their interdependence is often illustrated through the impact of prevention or augmentation of an earlier KE on later KEs (OECD, 2016). The determinants for consideration of the WOE for essentiality relate to the collective evidence (both direct and indirect) in support for one or more of the important KEs in the AOP/MOA. The evidentiary value of essentiality in the MOA quantitative confidence score is considerable. However, generating such essentiality data for each specific KE is neither practical, nor is it necessary. If it is demonstrated that preventing an early KE prevents the downstream KE(s) and adverse outcome, then essentiality is strongly supported for the pathway. Counterfactual experiments test whether the effect of interest still occurs when a putative causal step is prevented under conditions that would otherwise produce the effect of interest (Borgert et al., 2015) . Consider, for example, a nuclear receptor hypothesized MOA. When a knock-out or antagonist is able to ameliorate responses downstream from a KE there is considerable confidence not only that this specific KE is essential, but also that the chemical acts via this MOA. Similarly, knock-in models allow for generation of counterfactual evidence, which, like antagonism, is strong support for the hypothesized MOA. Thus, the score for the essentiality criterion may be determined by the highest score given to any KE within the hypothesized MOA pathway. For example, in the method we propose, if there are strong data from a knock-out test model of an early KE which indicates downstream KEs do not occur, the entire pathway (all KEs) would be afforded a score of 3 for strong evidence. Inconsistent evidence of essentiality is also possible for a MOA. For example, observations of increased tumors or cell proliferation in a target organ in a receptor knock-out animal could be considered as strong counter evidence in the evaluation of activation of that specific receptor as a KE in the hypothesized MOA, with the caveat that, in weighing such evidence, one would need to consider whether the knock-out stimulated other pathways that could lead to the adverse outcome.
Derive the composite score for each KE and KER (step 4)
The quantitative evidence rating for each KE/KER (e.g., 3 ¼ strong evidence) is multiplied by the weight assigned to each evolved Bradford Hill causal criterion/sub-criterion (e.g., 0.4 for essentiality) to obtain the KE score (e.g., 3 Â 0.4 ¼ 1.2). However, all KEs/KERs are not necessarily weighted the same. This is because for a given adverse outcome, often the later KEs leading to the adverse outcome are the same for each of the hypothesized MOAs. These later KEs are often indicative of the disease process, whereas the MIE and earlier KEs are more chemical-specific. For example, in rodent liver cancer, the late KE of clonal expansion of pre-neoplastic foci/nodules and the key event or adverse outcome of liver cancer are biologically the same whether produced by a chemical acting via a mutagenic MOA or a chemical that causes liver cancer by a receptor-mediated (e.g., PPARa) MOA (see Fig. 2 ). In other words, the later KEs (especially when they converge) are of much less evidentiary value in evaluating data in support of the WOE for a hypothesized MOA. Thus, the earlier, more diagnostic KEs are afforded more weight than the later, downstream, more general biological events associated with typical disease progression (e.g., hyperplasia, clonal expansion, etc.). In conducting the WOE confidence scoring of later KEs, one approach initially considered was to eliminate from the evaluation all of the common KEs across the two (or more) hypothesized MOAs. This would seem to eliminate analyses that may have limited probative value in determining a confidence score for MOAs based on mechanistic and animal data; however, it is likely that information on these later KEs and the adverse outcome (AO) will be crucial in conducting the subsequent human relevance and species concordance steps of the MOA framework. Furthermore, it would be incorrect to imply that one could score a hypothesized MOA for causality based solely on information on early KEs. Even though the early KEs provide the most evidentiary value for determining the confidence in an MOA, from a causal perspective, it is necessary to evaluate the complete body of evidence, including quantitative prediction models (when available) that establish the linkage of these early KEs to the later KEs and the AO. In our initial proof of concept case example, the later KEs are afforded 10% of the probative value of the early KEs; alternative weightings are included in the preliminary sensitivity analysis presented in Section 4. Similar to the allocation of weights for each evolved Bradford Hill causality consideration, this evidentiary value judgment for adjusting scoring of later KEs is proposed as a preliminary basis to demonstrate the utility of the method and to solicit additional input from the broader regulatory scientific community.
2.4. Integrate the evidence of causality for the MOA (step 5) and compare the quantitative scores for the hypothesized MOA (step 6)
To calculate the overall WOE confidence score for a hypothesized MOA, KE scores are summed and normalized by dividing by the maximum possible score and then multiplying by 100. This simple normalization procedure allows for comparison of quantitative confidence scores in cases where the number of KEs differs between hypothesized MOAs. Total scores may be negative if, for a hypothesized MOA, there is strong counter evidence for several of the early, most diagnostic KEs.
The MOA confidence score has greatest value for application in hazard characterization or risk assessment in comparative consideration across potentially operative MOAs. It is envisaged that the relative difference between the confidence scores of hypothesized MOAs is informative as a basis to distinguish the extent of supporting data for identifying the likely operative MOA. Scoring of specific elements of hypothesized MOAs (e.g., essentiality) is also helpful in identifying appropriate areas of focus for chemicalspecific research. At this early stage of method development, only general guidance on interpreting comparative MOA confidence scores is possible. For example, confidence in the extent of the supporting data associated with a higher numerical range (e.g., 75 to 100) potentially could be considered as sufficient to identify the likely operative MOA (i.e., the MOA for which confidence in the supporting data is greatest). A range of lesser values (e.g., 0 to 25) could be considered indicative of low confidence that a hypothesized MOA is supported. Scores that are negative would indicate that it is highly unlikely that the chemical is acting via that hypothesized MOA, with a larger negative value being reflective of stronger counter evidence. The magnitude of the variation in degree of confidence for the supporting data for hypothesized MOAs could also contribute to identifying relative research priorities across potential MOAs. This approach may be particularly informative for identifying and prioritizing further research areas to address specific data needs that would provide greater evidentiary value for increasing the WOE of specific KEs or KERs or evolved Bradford Hill considerations (such as essentiality).
Case example: clofibrate and rodent hepatocellular carcinomas
To illustrate the application of the quantitative MOA confidence scoring method, an analysis is provided using MOA data for clofibrate, a chemical that is a known rodent hepatocarcinogen. The data and lines of evidence used are based on a published review by an expert panel assembled to evaluate the PPARa MOA (Corton et al., 2014) , with additional consideration of clofibrate specific data and MOA analysis drawn from Klaunig et al., 2003 and IARC, 1996 . Two hypothesized MOAs are evaluated in this case example: 1) the hypothesis that clofibrate causes rodent liver tumors by a PPARa MOA; and 2) the hypothesis that clofibrate causes rodent liver tumors by a mutagenic MOA. This enables demonstration of the side-by-side comparison of numerical confidence scores for these alternative MOAs and illustrates their role in delineating the more likely operative MOA (i.e., best supported) between the two. The extent of support for the biological plausibility of the two pathways (PPARa and mutagenic MOAs), both of which are well documented, has been assumed to be similar and is not considered further here. Rather, chemical-specific supporting data for the remaining evolved Bradford Hill causal considerations are evaluated for the KEs/KERs of each MOA (Fig. 2) as a basis to apply the quantitative confidence scoring method described herein. Clofibrate is one of several therapeutic agents, industrial and pesticidal chemicals that cause peroxisome proliferation in rodent liver, both in mice and in rats. The molecular and cellular events by which PPARa activators induce rodent hepatocarcinogenesis have been extensively studied and elucidated. Following absorption, distribution and metabolism, the first event begins with the chemical binding and activation of the PPARa in hepatocytes. PPARa regulates the transcription of different classes of genes, including those involved in cell proliferation and apoptosis. Alteration of expression of these genes in rodent liver leads to increases in hepatocellular proliferation and corresponding decreases in hepatocyte apoptosis in the liver. Subsequently, pre-neoplastic foci, arising both spontaneously or through indirect DNA damage, have a selective growth advantage resulting in sustained cell proliferation compared to the surrounding parenchyma. Additional mutational or epigenetic changes in cells comprising these altered hepatic foci or nodules may occur, eventually leading to hepatocellular adenomas and carcinomas. The hypothesized MOA of PPARa-induced tumors in rodent liver is depicted in Fig. 2 . The MOA is organized as the sequence of KEs beginning with activation of PPARa, and proceeding through subsequent KEs culminating with liver tumor development. A summary of the WOE, including evidence which is supportive of, as well as potentially inconsistent with, the PPARa MOA for clofibrate is provided in Table 6 .
In Table 7 , the qualitative rating of evidence is summarized for each KE. These scores are developed in the context of the defining questions presented in Table 3 , using the qualitative ratings and scores described in Table 4 . The weights assigned for each of the evolved Bradford Hill causal considerations are those described in Table 5 . Biological plausibility of the pathway is assumed, and thus not scored here; the WOE based on extensive chemical-specific data for the remaining evolved Bradford Hill causal considerations indicates strong support that clofibrate can operate via this pathway. Note that in a full analysis a detailed rationale for each rating would be included.
In Table 8 , the composite scoring is presented. This begins with calculating a score for each KE by first multiplying the KE WOE rating (for each causality consideration) by the weight assigned to each evolved Bradford Hill causal consideration, and then summing these values. As indicated in Table 8 and discussed in Section 2.3.2, in this initial proof of concept case example, the later KEs are afforded 10% of the evidentiary value of the early KEs because these Table 6 Qualitatively evaluate the comparative WOE for clofibrate acting via a PPARa MOA (extracted from Klaunig et al., 2003 and Corton et al., 2014) a,b (step 2).
KE #1: Activation of PPARa Supporting Data: Issemann and Green (1990) reported concentration related activated reporter constructs in vitro, exhibiting less potency than the other fibrates tested. PPARa null mice had no increases in liver weight, hepatic peroxisome proliferation, or mRNA levels compared to the wild-type mice when given clofibrate at 0.5% in the diet for 2 weeks (Lee et al., 1995) . [Indirect evidence includes: induction of acyl CoA oxidase (peroxisomal enzymes) and induction of CYP4A: After exposure to PPARa agonist, clofibrate increases peroxisomal enzyme activity detected within days of initial exposure (Barber et al., 1987; David et al., 1999; Isenberg et al., 2000; Mitchell et al., 1985) . Pharmaceutical and industrial chemicals induce peroxisome proliferation in rodent liver e (e.g., WY-14643, gemfibrozil, fenofibrate, benzafibrate, ciprofibrate, DEHP, PFOA, etc.) (Corton et al., 2014) . Liver fatty acid binding protein and CYP4A are induced in wild type but not clofibrate PPARa null mice (Lee et al., 1995) . Peroxisome proliferation evidence in wild type but not PPARa null mice (Lee et al., 1995) .] Potentially Inconsistent data: There are some examples where PPARa activation alone does not consistently lead to liver cancer (Corton, 2008) . (Note: since nuclear receptor activation is believed to be an essential, but not necessarily sufficient, event, depending upon the length of the study, dosing, etc., the incidence of later key events (i.e. liver tumors) will always be less than that for early key events, and may be zero. Therefore, although included as "potentially inconsistent" these findings are not necessarily definitively inconsistent with the hypothesized MOA.) References: Barber et al., 1987; Corton et al., 2014; David et al., 1999; Gottlicher et al., 1992; Isenberg et al., 2000; Issemann and Green 1990; Lee et al., 1995; Mitchell et al., 1985 KE #2: Alteration in Cell Growth Pathways Supporting Data: Increased expression of genes encoding peroxisomal enzymes found in wild type, but not clofibrate treated PPARa knock-out mice (Lee et al., 1995) .
[Indirect evidence includes: expression of peroxisomal genes and PPARa mediated expression of cell cycle, growth and apoptosis: alteration of growth control genes by PPARa activators was not observed in PPARa null mice (Corton et al., 2014) Barrass et al., 1993; Eacho et al., 1991; Goll al., 1999; Marsman et al., 1992; Tanaka et al., 1992; Busser and Lutz, 1987; Amacher et al., 1997 There is extensive documentation of scientific acceptance of the biological plausibility of the PPARa MOA pathway leading to liver tumors in rodents (e.g., Corton et al., 2014) . Essentiality 
Multiple Studies Support KE and KER
a Qualitative ratings are indicated by þ or À and quantitative scores are indicated by the numerical values in parentheses. b Narrative (with references, as applicable) of the existing or de novo analysis which characterizes acceptance by the scientific community of the mechanistic basis for the steps in the pathway leading to the adverse effect (e.g., description of the biological plausibility analysis of an existing AOP or MOA pathway). Note: Pending additional development and case examples, biological plausibility is addressed only as a narrative at this time (see text for details). c In evaluating Essentiality, focus is on the KEs; in evaluating Empirical Support, Consistency and Analogy, emphasis is on KERs (see OECD, 2016 for details).
later KEs are indicative of the disease, not the MOA causing the disease. The overall composite score is calculated as the sum of the scores of each of the KEs normalized by dividing the sum by the maximum possible score and then multiplying by 100. The composite MOA confidence score of 83 indicates a high level of confidence that clofibrate produces rodent liver tumors by a PPARa MOA.
Hypothesis: rodent liver tumors induced by clofibrate are caused by a mutagenic MOA (step 1)
The hypothesized mutagenic MOA for induction of liver tumors in rodents is depicted in Fig. 2 as a sequence of specific KEs. Following absorption, distribution and metabolism, the MIE is reaction with DNA leading to promutagenic lesions. The next KE is insufficient/misrepair leading to mutations in key genes. Succeeding KEs, in order of occurrence, are perturbation of liver cell growth and survival, clonal expansion of liver foci/nodules, and liver tumor formation. The later KEs are disease-specific and therefore the same in both hypothesized MOAs. As emphasized by Eastmond, 2012 and MacGregor et al., 2015 , the body of genotoxicity evidence needs to be systematically examined, taking into account for each of the studies, the array of doses/concentrations tested, phylogenetic order and nature of change (e.g., whether the interaction with DNA is primary or secondary effect of cytotoxicity). This case example, developed for illustrative purposes, is based on consideration of the clofibrate-specific database, as reviewed by IARC, 1996, Klaunig et al., 2003 and Corton et al., 2014. This case example illustrates the necessity and value of scoring counter evidence. Clofibrate has been tested for genotoxicity in many assay systems and the results have been uniformly negative, particularly in mutagenicity assays (IARC, 1996; Klaunig et al., 2003; Corton et al., 2014 and Supplemental Material) . Clofibrate is not mutagenic in Salmonella typhimurium in the presence or absence of microsomal preparations. In Saccharomyces cerevisiae, clofibrate did not induce gene conversion or mitotic recombination. In single studies, clofibrate did not induce unscheduled DNA synthesis in cultured hepatocytes or DNA strand breaks in L1210 cells. Clofibrate was not mutagenic in Chinese hamster lung V79 cells in the presence of a rat hepatocyte metabolic activation system and did not induce resistance to 6-thioguanine in the same cells (Dayan et al., 1985) . It did not induce chromosomal aberrations in three studies with mammalian cell lines, and it did not induce micronucleus formation in rat hepatocytes. There was no evidence of DNA adduct formation in livers of male F-344 rats administered three doses of 250 mg/kg at 24 h intervals. In whole animals, clofibrate did not induce unscheduled DNA synthesis in rat hepatocytes, and it did not induce sister chromatid exchange in rat peripheral blood lymphocytes or bone marrow cells of Chinese hamsters. Oral treatment of Sprague Dawley rats with radiolabeled clofibric acid at 225 mg/kg did not lead to detectable radioactivity associated with liver DNA, although protein binding was demonstrated (von D€ aniken et al., 1981) . Table 9 provides a summary of the extent (and overall pattern) of the evidence that is supportive or inconsistent with each KE for the hypothesized mutagenic MOA, including nature of endpoint, test system and dose-response. The qualitative rating of evidence is summarized for each KE in Table 10 using the same scale as that used for the PPARa MOA (as described above and in Table 4 ) and numerical scores for each KE are presented in Table 11 . The weights assigned for each of the evolved Bradford Hill causal considerations are those described in Table 5 using the same approach as was applied for the PPARa MOA analysis.
From an AOP perspective, the broader biological database indicates considerable plausibility of mutagenic MOAs for a number of chemicals involving direct interaction with DNA, fixation of mutations in clonal expansion and subsequent tumors. However, the extensive chemical-specific data for clofibrate indicate strong counter evidence that it induces tumors through a mutagenic MOA (i.e., this chemical is not DNA reactive and does not result in early, direct damage to DNA (KE #1) or insufficient DNA repair or misrepair of DNA (KE #2)). The composite score for the hypothesized mutagenic MOA, calculated in the same manner as for PPARa MOA, is presented in Table 11 . The composite MOA confidence score of À44 indicates that the weight of available evidence is inconsistent with the hypothesis that clofibrate produces rodent liver tumors by a mutagenic MOA.
Compare the quantitative confidence scores for the hypothesized PPARa and mutagenic MOAs (step 6)
A side-by-side comparison of the confidence scores for the two hypothesized MOAs allows one to draw conclusions about which MOA is more likely to be operative based on the extent of evidence There is extensive documentation of acceptance of the biological plausibility of the PPARa MOA pathway leading to liver tumors in rodents (e.g., Corton et al., 2014 b Narrative (with references, as applicable) of the existing or de novo analysis which characterizes acceptance by the scientific community of the mechanistic basis for the steps in the pathway leading to the adverse effect (e.g., description of the biological plausibility analysis of an existing AOP or MOA pathway). Note: Pending additional development and case examples, biological plausibility is addressed only as a narrative (see text for details).
for each hypothesized MOA. The value of this comparative analysis is that it documents a consistent and transparent approach for integrating evidence for each hypothesized MOA in determining potential human health hazards and for informing dose-response analysis for quantifying potential risks. (Note: for documenting the application of the MOA framework in its entirety, we briefly present in the Supplemental Material a summary of the human relevance analyses of the PPARa-induced rodent liver tumor MOA that has been previously reported (Klaunig et al., 2003; Corton et al., 2014) ). The confidence scores help to illustrate the degree of scientific evidence in support of the conclusions that it is highly likely that clofibrate causes rodent liver tumors by a PPARa MOA and highly unlikely that a mutagenic MOA is operative. On a relative basis, the difference between the MOA confidence scores is greater than 120 points, indicating the WOE for clofibrate operating via a PPARa MOA to induce liver tumors in rodents is substantially greater than the WOE that clofibrate operates by a mutagenic MOA. In this manner, the quantitative confidence scoring method adds dimension to a WOE evidence analysis, which can be particularly useful in the process of documenting and demonstrating "sufficiently, scientifically justifiable MOA information." As illustrated in Table 7 , for the PPARa MOA the only KE judged to have weak evidence was KE #2 (alterations in cell growth pathways). In this case, while the data gap exists and can be identified in the qualitative analysis, the quantitative confidence scoring approach shows that there is sufficient evidence based on indirect evidence and KER to rely on KE #1 and KE #3 to bridge the gap for KE #2. This is because perturbations in cell growth pathways cannot occur without alterations of these pathways, so it may not be necessary to conduct additional research focused on expanding confidence in this MOA for clofibrate. In other words, while having additional, stronger evidence for KE #2 could increase the numerical confidence score, the overall score (MOA Confidence Score ¼ 83) is already at a level where the PPARa MOA is judged to be highly likely to be operative, and the limited value in collecting additional data for this KE should be considered before launching additional studies.
The quantitative MOA confidence score of À44 for the hypothesized mutagenic MOA is also informative as it illustrates the importance of analyzing and integrating (scoring) negative, counter Table 9 Qualitatively evaluate the comparative WOE for clofibrate Acting via a mutagenic MOA (extracted from Klaunig et al., 2003 and Corton et al., 2014) a (step 2). Barrass et al., 1993 , Eacho et al., 1991 , Goll et al., 1999 , Marsman et al., 1992 KE #4: Clonal expansion of neoplastic foci (KE#4) b
Supporting data: Enhanced heptocarcinogenicity of N-nitrosamines in rats and hamsters when co-administered with clofibrate. Potentially Inconsistent data: N/A References: Cattley et al., 1994 , Hosokawa et al., 1989 , Mizumoto et al., 1988 , Mochizuki et al., 1983 KE #5: Hepatic Tumors b Supporting data: Foci development leading to liver tumors. Potentially Inconsistent data: N/A References: Cattley et al., 1994 , Hosokawa et al., 1989 , Mizumoto et al., 1988 , Mochizuki et al., 1983 N/A ¼ not available. a References cited in this table have been extracted from Klaunig et al., 2003 and Corton et al., 2014 ; also see Supplemental Material.
b Note e Although the evidence for these KEs are indicated as being consistent with a mutagenic MOA, these KEs are biologically the same whether produced by a chemical acting via mutagenic MOA or a chemical that causes liver cancer by another MOA. There is extensive documentation of acceptance of the biological plausibility of the Mutagenic MOA pathway leading to liver tumors in rodents (e.g., Cohen and Arnold, 2011) . Essentiality 
a Qualitative ratings are indicated by þ or À and quantitative scores are indicated by the numerical values in parentheses. b Narrative (with references, as applicable) of the existing or de novo analysis which characterizes acceptance by the scientific community of the mechanistic basis for the steps in the pathway leading to the adverse effect (e.g., description of the biological plausibility analysis of an existing AOP or MOA pathway). Note: Pending additional development and case examples, biological plausibility is addressed only as a narrative (see text for details). c In evaluating Essentiality, focus is on the KEs; in evaluating Empirical Support, Consistency and Analogy, emphasis is on KERs (see OECD, 2016 for details).
evidence. In this case example, for the hypothesized mutagenic MOA, there is strong evidence that clofibrate does not cause KE #1 or KE #2, both necessary to initiate this pathway and the large negative score reflects the strong counter evidence for this MOA and adds dimension to the WOE conclusion that clofibrate is highly unlikely to operate via this MOA. Furthermore, the quantitative MOA confidence scoring method can distinguish cases where there is weak, or little to no evidence for one or more early KEs from a case where there is counter evidence for these early KEs.
Preliminary sensitivity analysis
As indicated, the selection of values for weighting the evolved Bradford Hill causal considerations was consistent with the hierarchy described in Meek et al. (2014b) and the OECD (2016) based on their relative evidentiary contribution to WOE determinations for hypothesized AOPs/MOAs. A preliminary sensitivity analysis (Table 12) shows, for the datasets used in the case example, there is not a great deal of impact upon the confidence scores if the evolved Bradford Hill causal considerations are weighted equally.
A preliminary sensitivity analysis was also conducted to evaluate the effect on confidence scores as a function of the value selected for weighting later KEs (Table 12 ). In this clofibrate MOA dataset, eliminating the later KEs altogether (i.e., assigning these KEs a weight of 0) had little effect on the confidence scores. However, if the later KEs were weighted equal to the early KEs (i.e., all KEs assigned a weight of 1), while only a minor effect was seen on the PPAR-a MOA confidence score, for the mutagenic MOA confidence score, a large effect was observed. This was the case even though there is strong counter evidence for the early KEs for a mutagenic MOA. In other words, if the later KEs, which are indications of disease processes and progression, are assigned equal weight to the early KEs that are much more diagnostic of specific MOAs, then the confidence score for a specific MOA can be artificially inflated by a substantial degree. This outcome would dilute the value of the quantitative confidence scoring method for comparing hypothesized MOAs. Therefore we do not recommend assigning later KEs the same weight as earlier KEs. At this early stage of method development, we also do not recommend eliminating common KEs across the two (or more) hypothesized MOAs from the quantitative confidence scoring approach since it is likely that information on these later KEs (and the adverse outcome) will a In this example, these later KEs have been assigned 10% of the evidentiary value of the earlier KEs (see Section 2.3.2 for discussion of evidentiary value of early and later KEs). b Narrative (with references, as applicable) of the existing or de novo analysis which characterizes acceptance by the scientific community of the mechanistic basis for the steps in the pathway leading to the adverse effect (e.g., description of the biological plausibility analysis of an existing AOP or MOA pathway). Note: Pending additional development and case examples, biological plausibility is addressed only as a narrative at this time (see text for details).
Table 12
Preliminary sensitivity analysis. a Biological plausibility is included in this prototype confidence scoring approach as a critical element of the causal analysis, but for the chemical-specific MOA confidence score, biological plausibility has not been weighted or scored at this time; see text for details.
be crucial in conducting the human relevance and species concordance step of the analysis. Clearly, the evidentiary value judgment for adjusting scoring of later KEs will benefit from additional input from the wider regulatory scientific community. It will be important to conduct a more thorough sensitivity analysis after case examples for several other chemicals and a variety of MOAs have been developed.
Discussion
The MOA framework, in use for over a decade, has contributed to increasing transparency in organizing mechanistic studies and integrating evidence, and has proven to be an effective method for identifying strengths and weaknesses in the data, including specific inconsistencies, uncertainties and data gaps (and their relative priority). The framework provides a structured systematic approach for consideration of all available, relevant and reliable data, and explicitly documents the comparative extent of support (WOE) for the KEs/KERs and their sequence leading to the adverse outcome. While the framework does not provide a "yes or no" answer on the sufficiency of data in support of a specified MOA, it provides a means to evaluate and judge the overall pattern of WOE in support of a specific MOA in relation to potential alternatives. The WOE outcome relies on evidence-based, scientific judgment relevant to evaluating and integrating evidence and drawing conclusions based on inferences as described by Rhomberg et al., 2013 and Linkov et al., 2015 . It is necessarily predicated on hazard and mechanistic data selection, analysis (quality, reliability, validity of the method/study design, dose-response, etc.) and integration using clearly delineated objective criteria (Fenner-Crisp and Dellarco, 2016) . The MOA framework and approach has continued to evolve (USEPA, 2005; Boobis et al., 2006 Boobis et al., , 2008 Carmichael et al., 2011; Elcombe et al., 2014; Budinsky et al., 2014; Corton et al., 2014) . For example, the WHO/IPCS MOA framework update (Meek et al., 2014a,b) framed MOA analysis in an iterative problem formulation context and introduced the concept of comparative analysis to consider the relative extent of evidence supporting hypothesized MOA(s). The evolved Bradford Hill causal considerations were also updated based on increasing experience in their application (Meek et al., 2014a,b) . More recently, additional experience has been acquired in the development and documentation of AOPs for an international knowledge base OECD, 2016) .
The proof of concept for quantitative confidence scoring described here is proposed as a potential contribution to this evolution to further improve the utility of MOA analysis and to promote greater consistency of application within and among different organizations. In the absence of such a quantitative comparative approach, determinations of the extent of evidence supporting various MOAs typically rely upon the experience of risk assessors to recognize and interpret the pattern of evidence. In a number of cases, the qualitative variations in the confidence in supporting data for potential modes of action may be sufficiently clear that quantitation is considered unnecessary. However, a quantitative comparative approach has potential to facilitate understanding of the confidence in reaching conclusions about the likelihood of a particular MOA, based on transparently documented WOE causal analysis scoring for potential MOAs. The quantitative confidence scoring method adds dimension to a comparative MOA WOE evidence analysis, which can be particularly useful in communicating to non-specialists such as risk managers, policy decision makers, and the public.
Based upon the experience gained in applying the MOA confidence scoring approach, if the approach is to be used in a comprehensive chemical-specific evaluation (i.e., beyond a case example), written characterization of the quantitative evaluation would benefit from communication of the detailed information on sources of data used in modeling. In such comprehensive evaluations, it's imperative that a narrative discussion of the weights used in the evaluation (preferably supported by a sensitivity analyses) be included, along with an overall evaluation of the plausibility of the outcome. In addition, the nature of the data and the assumptions supporting the essentiality score for a hypothesized MOA should be explicitly documented (i.e., by specifying the extent and nature of direct and indirect evidence for each of the KEs). In some cases, substances with larger, higher quality datasets with specific experimental evidence pertinent to essentiality will logically support such an inference, whereas in other cases, less experimental data may be available and assumptions may predominate. The quantitative scores are designed to reflect such differences. MOA hypotheses that entail biological processes that are novel or poorly established should be explained and documented in the MOA framework analysis, but caution should be exercised in proceeding with the quantitative confidence scoring method. There may be some instances, particularly for prioritizing research, where it is advantageous to conduct quantitative confidence scoring of alternative MOAs that differ in overall scientific understanding (e.g., a case where the extent of supporting evidence on the biological plausibility of the hypothesized MOAs varies). Development of more case examples focusing on a broader set of MOAs may be informative in this context. It is also important to note that the scoring is dependent upon the available data sets analyzed at the time. As future research results become available, confidence scores for reasonably hypothesized MOAs are expected to change, reflecting the iterative nature of risk assessments in general; confidence scores for MOAs with limited available data are likely to change the most over time.
In MOA analysis for a specific chemical, the evaluation focuses on the extent of supporting evidence that it causes an adverse effect through the hypothesized MOA, whereas for an AOP, evidence relates to the extent of support based on amassed information on the disease process for the biological cascade of KEs between the molecular initiating event and adverse outcome. For AOPs, documentation of the extent of supporting evidence for the disease process addresses a subset of the evolved Bradford Hill causal considerations based on testing by a wide range of stressors (i.e., biological plausibility and empirical support for KERs and essentiality of KEs). As noted, biological plausibility is included in this prototype confidence scoring approach as a critical element of the causal analysis of a biological pathway, but has not been weighted or scored at this time for the chemical-specific data. This relates in part to the status of documentation of the AOP for PPARa activation leading to liver tumors in rodents, which has been published as a MOA (Corton et al., 2014) , but not yet incorporated fully into the AOP Wiki; and, in part, for the need for additional consideration of case examples with documented AOPs, which have not yet been fully considered. In this context, evaluating approaches for scoring biological plausibility has been identified as a priority area for development, including further focus in additional case examples (Table 13 ). Further consideration of additional experience in assessing the evolved Bradford Hill causal considerations, particularly in AOP development, will be relevant to refinement and potential simplification of the MOA confidence scoring method.
A conclusion of our work is that, to better characterize hazard and risk, it is necessary to utilize all available data and consider both supportive and potentially inconsistent data, including counter evidence, based on systematic consideration of direct and indirect evidence collected at different levels of biological organization. Whether described as quantitative or semi-quantitative, the design of this initial approach could be viewed by some as complex and indeed it may be more intricate than is necessary. As more experience is gained, the method will be refined and may become leaner and more efficient over time (i.e., greater simplicity in application). This derives from previous experience that several of the evolved Bradford Hill causal considerations are more appropriately applied in the context of the MOA/AOP, overall, rather than to each KE/KER. However, previous experience has also illustrated that explicit delineation in early stages of the WOE considerations for each KE/KER component increases transparency and facilitates evolving a common understanding of influential elements. Clearly, for quantitative confidence scoring, experience gained in developing additional case examples is likely to inform refinement and optimization of the method. It is also likely to increase common understanding of the nature of supporting data that optimally informs MOA analysis.
Recently, Smith et al. (2015) described an approach for considering mechanistic characteristics of known carcinogens to organize and apply data in informing causal inference of carcinogenic hazard to humans. However, such an approach is qualitative and does not systematically integrate available data at various levels of biological organization using causal analysis. Even if early biological responses/perturbations are detected, these observations are not necessarily predictive (Thomas et al., 2012) for adverse effects in living organisms since they do not take into account adaptive or homeostatic mechanisms relative to dose and duration of exposure. In comparison, the confidence scoring method for evaluating MOAs presented here can be viewed as a step towards developing scientifically thorough, objective, and transparent approaches for integrating mechanistic information into chemical hazard and risk evaluations as recommended by NRC (2014) . Although this paper presents a simplified weighting approach, the quantitative confidence scoring method for evaluating MOAs could potentially be developed into a Bayesian or multi-criteria decision analysis model (Linkov and Moberg, 2012; Linkov et al., 2015) , which may enable better integration of expert confidence and its statistical evaluation (e.g., p value) than could be derived from relevant expert knowledge alone. The statistical confidence element in this model originates from the degree of certainty determined in each lab study. The expert confidence element originates from an MOA assessor's evaluation of the quality of the empirical evidence, professional judgment of the uncertainty in each WOE rating, and perception of the logical implications of the observed data (e.g., relationship between the KE and its predecessors). Inclusion of Bayesian methods that improve integration of statistical confidence and expert confidence (Linkov et al., 2011) has the potential to address important data gaps when empirical data may be limited.
In applying the quantitative confidence scoring method, it is important to understand its strengths and limitations. The method can neither enhance nor alter the available data, nor does it interpret the data. What the method provides is a simple, straightforward approach that allows for the numerical comparison of the evidence underpinning each hypothesized MOA under consideration. Further, it allows for identification of potential data gaps, and assists in prioritizing these for research. For example, the value of addressing specific data gaps could be gauged by conducting a sensitivity analysis for impact on the comparative confidence score in which the numerical values are varied to estimate the potential "value added" for addressing specific data gaps. Based upon the degree of certainty needed for the intended regulatory applications identified during the problem formulation step, the confidence scoring method could also indicate where development of "consistency" and "analogy" be evaluated for each KE/KER, or should they be treated similar to "essentiality," with one score assigned across the entire MOA? Is the approach for considering and scoring "essentiality" for the entire MOA satisfactory? 2. Qualitative evaluation of the evidence in support of or inconsistent with the KEs based on the evolved Bradford Hill causal considerations (Section 2.3.1 Weights for Evolved Bradford Hill Causal Considerations) a. What are the key considerations and specific rationales when deciding how much weight to assign to each evolved Bradford Hill causal consideration? For example, is a 5% weight for "analogy" sufficient in all cases, especially for case examples that rely heavily on data from analogs? 3. Quantitative rating each KE/KER using the evolved Bradford Hill causality considerations for confidence in causality (Section 2.3.2 Rate and Score Each KE in the MOA) a. How to ensure consistency in weighing the evolved Bradford Hill causal considerations in relation to KEs/KERs for example, what steps would be involved for weighing the lines of evidence for KEs/KERs so that evaluators are less likely to reach different conclusion? b. Could KERs be weighted differently based on the overall scientific understanding of each? For example, rather than having each KER rated based on weight of evidence, a lower score would be assigned to KERs with lower scientific confidence or scientific credibility. 4. Derivation of the composite confidence scores (Section 2.4 Calculating and Interpreting MOA Scores) a. What are some key considerations for determining the amount of evidentiary value (e.g., 25%, 15%, 10%, etc.) to assign to KE/KERs, specific and non-specific to the MOA? Should the KEs/KERs be weighted equally in all cases? 5. Comparison of the confidence scores for the hypothesized MOAs and selection of the most likely operative MOA(s) (Section 3.3 Side-by-Side Comparison of Confidence Scores) a. In developing additional case examples to refine the method, what MOAs should be considered? What types of datasets would be most useful to inform regulatory risk assessments for different types of substances (e.g., consumer product chemicals, pesticides, etc.). What will be the utility of the method when using high throughput/high content data for substances currently lacking extensive toxicity profiles? b. How might the method be improved upon by employing a multi-criteria decision analysis model, or a Bayesian approach? What datasets would be needed and how would the necessary input be obtained by experts in MOA analyses for development and verification of these methodologies. c. Could an efficient, web-based expert elicitation method be designed to enable broader scientific input for reviewing the data, evaluating the lines of evidence and determining the confidence scores for each KE? And for sensitivity analyses, updating analyses and scoring as new data become available? d. What are different possibilities of interpreting the comparative WOE confidence scores between different hypothesized MOAs that could inform the selection of the most scientifically supportable low dose extrapolation method for human health risk assessment? e. What are some approaches to equating the numerical scores with qualitative confidence statements (e.g., >75 ¼ high confidence, < 20 low confidence, etc.)? additional data is of relatively low priority. Even though the quantitative confidence scoring approach is at an early proof of concept stage, based on the advantages discussed above, additional development of the method is warranted. With future experiences gained in developing additional case examples, many of the topics described in Table 13 are expected to be addressed.
Conclusions
The quantitative confidence scoring approach proof of concept is offered as further evolution of MOA analysis. It is a systematic and explicit approach for evaluating a chemical dataset, using hypothesized MOAs and the evolved Bradford Hill causal considerations, to integrate evidence and derive confidence scores for potentially relevant MOAs. The components consist of: 1) a set of defining questions for each of the Bradford Hill considerations coupled with a WOE rating and scoring procedure to guide data evaluation and WOE determinations; 2) a procedure to score the evolved Bradford Hill causal consideration for essentiality at MOA pathway level based on the highest score achieved by any one of the unique KEs in the pathway; 3) a technique for including the supporting evidence of later KEs, even though these are disease-specific and not diagnostic of a MOA for a particular chemical, by affording less evidentiary value to later KEs than the earlier, more MOA-specific KEs; 4) hierarchical weighting of the evolved Bradford Hill causality considerations in a manner consistent with current practices for qualitative MOA (Meek et al., 2014a,b) and AOP (OECD, 2016) development; and 5) a straightforward arithmetic method to characterize the overall confidence score for each hypothesized MOA.
Given that characterization of relative confidence in supporting data for hypothesized MOAs is imperative to enable risk managers to distinguish best-supported options (i.e., those that are most certain), this quantitative confidence scoring method is proposed as a basis to enhance transparency and communication of the relative extent of the available evidence to risk assessment experts, less experienced practitioners, risk managers, and the public. It does so by permitting a side-by-side comparison using numerical scores to enable distinction between the extent of the supporting data for hypothesized MOAs for specific adverse outcomes, and in doing so, to better identify the more likely (i.e., best supported) operative MOA. The method not only improves the ability of assessors to consider more systematically and transparently the extent of supporting data for potential MOAs, it can also increase confidence in selection of appropriate dose-response extrapolation methods. Comparative MOA confidence scoring can also aid in distinguishing research priorities that could reduce uncertainty and increase confidence to better support and establish causality of MOAs for specific substances. In moving forward, it will be important to work with an expanding group of experts to develop additional case examples that represent a wide range of MOAs, documented AOPs and varying evidence (including high throughput/high content data for substances currently lacking extensive toxicity profiles) to improve the confidence scoring method.
